Cellulbiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum

S STROBEL, W G BRYDON, AND ANNE FERGUSON

From the Gastro-Intestinal Unit, University of Edinburgh and Western General Hospital, Edinburgh, Scotland

SUMMARY Intestinal permeability to probe molecules has been shown to correlate closely with the presence or absence of villous atrophy in a jejunal biopsy. The purpose of this study was to establish if there exist groups of patients with functional derangement of intestinal permeability but normal histopathology of the small bowel mucosa. In 135 patients a cellulbiose/mannitol permeability test was performed at the same time as jejunal biopsy. Diagnosis included coeliac disease, Crohn's disease, irritable bowel syndrome, idiopathic diarrhoea, self diagnosed food allergy, atopic eczema and postinfectious malabsorption. The value of the cellulbiose/mannitol test in identifying patients with abnormal jejunal biopsy histopathology was confirmed. The permeability test was abnormal in all 28 patients with partial or subtotal villous atrophy, and also in all 10 in whom there was a high intraepithelial lymphocyte count despite normal villi and crypts. Functional abnormality of the small intestine has not previously been reported in patients with this jejunal biopsy abnormality. Abnormalities of permeability were also found in patients with idiopathic diarrhoea, folate deficiency, postinfectious or traveller's diarrhoea, small bowel Crohn's disease, and atopic eczema. These results show that sugar permeability tests have more potential in clinical investigation than merely serving as screening tests before jejunal biopsy. There are groups of patients without morphological changes in the small bowel in whom intestinal permeability is abnormal.

Several abnormal features of transepithelial transport occur in diseases of the small intestine associated with villous atrophy. These include impairment in active absorption of various nutrients, reduction in the passive penetration of the epithelium by small probe molecules and an increase in the permeability to larger molecules of molecular radius greater than 0.5 nm. Such observations form the theoretical basis for several recently described tests of intestinal permeability,1-3 which measure the absorption or penetration of large and small probe molecules. The ratio of permeability for large versus small probes is increased in patients with coeliac disease4-5 and it has been suggested that an intestinal permeability test will provide one method for screening patients who should be submitted to jejunal biopsy.6

In the initial clinical assessments of these permeability tests, several patients with non-coeliac gastrointestinal disease6 7 or with atopic eczema8 have been described, in whom permeability ratios are abnormal. Thus there may exist groups of patients with functional derangement of intestinal permeability, in which the bowel is 'leaky' to large probes, even though histopathology is normal. Clearly, this could provide an entirely new approach to investigation of disorders of the jejunum although it will remain essential to interpret the results of such permeability tests in the knowledge of intestinal histopathology. We have performed, simultaneously, jejunal biopsy and a cellulbiose/mannitol sugar permeability test in order to determine if indeed these tests are complementary. One hundred and thirty-five patients were investigated, all of whom were undergoing investigation of diarrhoeal disease, malabsorption or possible food allergy. The results show not only that the sugar permeability test will predict all
patients with abnormal jejunal histopathology, but also that there exist a group of distinct clinical and pathological entities, where sugar permeability is abnormal despite unequivocally normal jejunal biopsy histopathology.

Methods

Patients and Volunteers
Fifteen normal volunteers who had not had jejunal biopsy (healthy laboratory and medical staff) age range 21–42 years, were used to establish a provisional normal range for the test. As the test solution contained lactose, a further five doctors, all clinically lactose malabsorbers (assessed by the breath hydrogen test after a lactose load) also participated in the test.

Biopsied Patients
Patients undergoing jejunal biopsy for conventional clinical indications – diarrhoea, suspected malabsorption, follow up of treated coeliac disease and possible food allergic disease – comprised the study group. There were 135 patients, an unselected sequential series of patients, whose ages ranged from 14–75 years. After the study had been completed, case notes were reviewed retrospectively and a final diagnosis made on the basis of all the clinical information including the result of the jejunal biopsy histopathology and disaccharidase assays but without knowledge of the result of the sugar permeability test. The final diagnoses are listed in Table 1.

Investigative Procedures
The procedures were performed mainly in out patients, who attend a clinical investigation suite staffed by nurses. After an overnight fast the patient reported at about 8 am, emptied his bladder and then swallowed a prepared Watson peroral biopsy capsule, with a few sips of water. Fifteen milligrams metochlopromide was given orally. Five minutes later the patient started to drink the sugar test solution, and this was consumed within five minutes. The position of the biopsy capsule was monitored by screening and when the capsule was beyond the ligament of Treitz, a biopsy was taken in the usual way and the capsule withdrawn. Patients fasted for a total of five hours after ingestion of the sugar test solution, with the exception of water, tea or coffee without milk or sugar which were allowed after 2½ hours. All urine passed within five hours of the sugar drink was collected, the volume measured and an aliquot stored at −20°C. The composition of the sugar test solution was as follows: 2 g mannitol, 5 g cellobiose, 20 g lactose, 20 g sucrose made up to 150 ml with tap water to give an osmolality of approximately 1500 mosm.

The jejunal biopsy was examined with a dissecting microscope and processed for conventional histopathological diagnosis. Subsequently all slides were coded and reviewed. The histology was classified as either unequivocally abnormal with partial or subtotal villous atrophy; essentially normal with normal villus and crypt architecture but with a high intraepithelial lymphocyte count (>40 lymphocytes/100 epithelial cells); and completely normal, with normal villus crypt architecture and normal intraepithelial lymphocyte count. Disaccharidases lactase, sucrase, trehalase and maltase were assayed by Dahlqvist’s method.

Mannitol and Cellobiose Assays
Mannitol
Mannitol in urine was measured by the method of Corcoran and Page, and is oxidised to formaldehyde by periodic acid. The formaldehyde reacts with chromotropic acid to form a purple complex which is measured at 570 nm absorbance.

Cellobiose
A new method, suitable for routine clinical diagnostic laboratories was developed – this avoided a need for quantitative paper chromatography. Cellobiose reacted with β-glucosidase to yield two molecules of glucose/cellobiose molecule. D-glucose was then measured using the hexokinase procedure with NADPH generation measured at 340 nm (see appendix). The hyperosmolar sugar solution used for this procedure was similar to several previously published studies and contained 20 g lactose. The Sigma β-glucosidase used in the measurement of cellobiose had lactose hydrolytic activity. In order to

Table 1 Diagnoses in volunteers and patients

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>N</th>
<th>L</th>
<th>Biopsied</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-biopsied</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N  – Normal volunteers</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L  – Lactase deficient clinical staff</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopsied</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N  – Normal (volunteers and healthy relatives of coelias)</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBS – Irritable bowel syndrome</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID – Idiopathic diarrhoea</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>‘FA’ – Self diagnosed food allergy – not substantiated on clinical investigation</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AE – Atopic eczema</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cr – Small intestinal Crohn’s disease</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UC – Ulcerative colitis</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I – Postinfectious diarrhoea (+ bacterial colonisation)</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H – Folate deficiency (presumed nutritional)</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M – Miscellaneous gastrointestinal disorders</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND – Coeliac disease (normal diet)</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFD – Gluten free diet prescribed</td>
<td>27</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Jejunal permeability and biopsy histology

Table 2  Urinary recoveries of cellobiose and mannitol (total and % ingested dose/5 hours) in normals and patients

<table>
<thead>
<tr>
<th>Disease</th>
<th>Mannitol/5 h ±SD (g)</th>
<th>Cellobiose/5 h ±SD (g)</th>
<th>Mannitol % x±SD</th>
<th>Cellobiose % x±SD</th>
<th>N°†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal volunteers</td>
<td>0.47±0.12</td>
<td>0.027±0.008</td>
<td>23.3±5.0</td>
<td>0.54±0.16</td>
<td>15</td>
</tr>
<tr>
<td>Irritable bowel syndrome</td>
<td>(0.39±0.17)*</td>
<td>(0.016±0.01)</td>
<td>(19.6±8.3)</td>
<td>(0.32±0.20)</td>
<td></td>
</tr>
<tr>
<td>Eczema (with C/M ratio)</td>
<td>0.42±0.012</td>
<td>0.026±0.012</td>
<td>21.0±5.8</td>
<td>0.51±0.25</td>
<td>11</td>
</tr>
<tr>
<td>Coeliac disease</td>
<td>0.31±0.12</td>
<td>0.044±0.013</td>
<td>15.6±6.2</td>
<td>0.82±0.26</td>
<td>4</td>
</tr>
<tr>
<td>(0.17±0.13)</td>
<td>(0.048±0.031)</td>
<td>(8.3±6.3)</td>
<td></td>
<td>(0.96±0.61)</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>0.28±0.11</td>
<td>0.043±0.017</td>
<td>14.2±5.4</td>
<td>0.86±0.33</td>
<td>7</td>
</tr>
<tr>
<td>Folate deficiency</td>
<td>0.23±0.08</td>
<td>0.040±0.02</td>
<td>11.4±4.2</td>
<td>0.79±0.41</td>
<td>5</td>
</tr>
</tbody>
</table>

* Results obtained by quantitative paper chromatography shown in brackets. 
† Individuals per group.

establish whether absorbed lactose interfered with the cellobiose assay, five normal subjects undertook sugar permeability tests on two occasions at least two days apart. In one test the sugar solution contained 20 g lactose and 20 g sucrose and in the other 40 g sucrose was used as the hyperosmolar agent. In addition five lactase deficient subjects undertook the sugar permeability test using the 20 g lactose, 20 g sucrose containing solution.

Expression of results
For each of the two administered probe molecules, cellobiose and mannitol, the percentage urinary recovery was calculated. The final ratio of percentage recovery of cellobiose to percentage recovery of mannitol was calculated. (Table 2).

Results
There were no practical problems associated with the combination of peroral jejunal biopsy and the sugar permeability test. The test solution was well tolerated. Two of the five lactase deficient volunteers reported loose bowel motions six to eight hours after ingestion of the sugar solution.

NORMAL RANGE
Urinary mannitol excretion was found to be within the range of previously reported values; cellobiose recovery rates as measured with the enzymatic assay were comparable with those measured by paper chromatography. In the five subjects used to study the effects of lactose on the measured urinary cellobiose, the per cent excretion of cellobiose when the lactose containing solution was administered was 0.60±0.13%; and when lactose was excluded from the solution, the mean percentage excretion cellobiose was 0.57±0.21%. By using Wilcoxon's rank sum test for pairs no significant differences between these two groups of measurements were present. In the five lactase deficient subjects percent cellobiose excretion was 0.47±0.24% (mean ± SD) with a range of 0.17-0.79%. In the 15 non-biopsied volunteers cellobiose/mannitol (C/M) excretion ratio was in the range as shown in the Figure with a mean of 0.023 and standard deviation 0.007, although it is noticeable that the distribution is skewed. Results in the five lactase deficient subjects ranged from 0.01-0.035. We have taken the upper limit of normal for the test as the mean + two standard deviations of results in 15 normal volunteers, namely 0.037.

RELATIONSHIP BETWEEN JEJUNAL BIOPSY
HISTOPATHOLOGY AND C/M RATIO
Of 135 patients studied, 80 had a C/M ratio within the normal range and 58 had ratios greater than 0.037. Correlation with histopathology is illustrated in Table 3. Not only did all 28 patients with partial or subtotal villous atrophy have an abnormal ratio, but so also did the 10 patients (including three treated coeliacs) with normal villi but high intraepithelial lymphocyte count.

C/M RATIO IN DIAGNOSTIC GROUPS
Of the patients in whom no significant jejunal disease was present, all but two had normal C/M ratios. Thus these comprised the nine normal subjects, 15 patients with irritable bowel syndrome and nine with unsubstantiated, self-diagnosed food

Table 3

<table>
<thead>
<tr>
<th>Histopathology of jejunum</th>
<th>C/M ratio normal</th>
<th>C/M ratio high (&gt;0-037)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>80</td>
<td>17</td>
</tr>
<tr>
<td>Partial/subtotal villous atrophy</td>
<td>—</td>
<td>28</td>
</tr>
<tr>
<td>Normal villi and crypts; high intraepithelial lymphocyte count</td>
<td>—</td>
<td>10</td>
</tr>
</tbody>
</table>
The two high ratios were borderline, with values being below 0.040. On the other hand, a clear relationship between jejunal histopathology and sugar permeability was evident in coeliac disease as illustrated in the Figure. C/M ratio was abnormal in all coeliacs ingesting a normal diet; those patients with entirely normal jejunal histopathology on a gluten free diet had normal C/M tests, and all of those with abnormal histopathology despite prescribed gluten free diet, had an abnormal ratio. On the other hand, abnormal ratios were found in five of 10 patients with idiopathic diarrhoea, all five folate deficient individuals, one of four patients with postinfectious or traveller’s diarrhoea, five of seven with small bowel Crohn’s disease and four of 13 with atopic eczema, despite the presence of normal villi in the jejunal biopsy. Biopsies from the patients with idiopathic diarrhoea, atopic eczema and folate deficiency had normal disaccharidase activities though three of these patients had a high intra-epithelial lymphocyte count. In the group classified as ‘miscellaneous’ C/M ratios ranged from 0.01 to 0.052. Abnormal results were obtained in patients with the following diagnoses: systemic lupus erythematosus, primary biliary cirrhosis, diarrhoea after gastric surgery, and short stature (a borderline result at 0.038).

**Discussion**

This prospective study confirms and extends other reports on the use of permeability tests in the investigation of patients with small bowel disease. The cellobiose/mannitol permeability test has a high patient acceptability and we have found that, by using an enzyme assay for cellobiose, it is possible to complete laboratory processing of a batch of tests within a single working day. Despite the use of a new method, values for cellobiose and mannitol excretion in normal subjects in this study are similar to those obtained in other centres, where cellobiose has been measured by chromatography. Theoretically, inclusion of lactose in the test solution might be considered inappropriate for there is the risk that absorbed lactose will interfere with the cellobiose assay. In a study carried out by Menzies, 0.09% of an ingested dose of 20 g lactose was excreted within 10 hours (18±5 mg lactose excreted, mean ± SD). Over twice as much lactose was found to be excreted in subjects with hypolactasia. The experiments which we undertook to evaluate this aspect of the test have been reassuring in that they show no significant difference between the measured excretion of cellobiose in the normal subjects who performed the test with and without lactose in the hyperosmolar sugar solution. The difference between the two groups was only 0.03%, equivalent to 1.5 mg glucose or 3 mg lactose. That is equivalent to 0.015% of the ingested dose, rather less than the 0.09% excretion reported by Menzies who used paper chromatography, and studied lactose excretion over 10 hours. Furthermore, we have found no difference in per cent cellobiose excretion when normal lactase deficient subjects have been compared with other normal subjects.

Thus the results of the study indicated negligible interference from lactose in the enzymatic procedure for the measurement of cellobiose. A sugar solution containing both lactose and sucrose is...
distinctly more palatable than one containing sucrose alone. For these reasons, and in order to introduce as few variables as possible between our test and those previously reported in the literature, we have retained as the standard test solution, a drink which contains cellobiose, mannitol, sucrose, and lactose.

Although the mechanism by which these sugars penetrate the epithelium is still hypothetical, the existence of at least two different sets of pores has previously been postulated,12 (0.4 nM diameter for mannitol, 0.52 nM diameter for cellobiose). In patients with untreated coeliac disease and villous atrophy, reduction in mannitol recovery is thought to be because of a reduction of pores available for diffusion as a consequence of low surface area, whereas the increased permeability to larger molecules may be via epithelial discontinuities (altered tight junctions, cell extrusion zones). The present study confirms that abnormal results are obtained in all patients with partial or subtotal villus atrophy in a jejunal biopsy, not only in coeliac disease but also in patients with postinfectious malabsorption.

Intraepithelial lymphocytes (IEL) are normal constituents of the small intestinal epithe
ilum. They can readily be counted in histological sections and, in man, normal values range from 10–40 IEL/100 villus epithelial cells.9 In animal experiments, increased intraepithelial lymphocyte counts occur predictably in intestinal mucosal cell mediated immune reactions.13 14 Mucosal cell mediated immune reactions are also associated with crypt hyperplasia and villus atrophy.15 In some patients with coeliac disease, on treatment, or shortly after gluten reintroduction, high intraepithelial lymphocyte count in an otherwise normal jejunal biopsy may be the only abnormality (Ziegler and Ferguson unpublished). Ten of the patients in this present series had essentially normal jejunal biopsy morphology, with normal villi and crypts, normal enterocytes but a raised intraepithelial lymphocyte count, and all of these patients had an abnormal sugar permeability test whether or not the diagnosis was coeliac disease. This is the first report of any significant abnormality in small intestinal function, associated with a high intraepithelial lymphocyte count and tends to support the concept that a high intraepithelial lymphocyte count is a significantly abnormal finding and may in man, as well as in animals, reflect mucosal cell mediated immune reactions. Precisely how the abnormal permeability to probe sugars is related to the immunological abnormality remains to be established.

The simultaneous use of a permeability test and jejunal biopsy has allowed us to identify individuals in whom cellobiose/mannitol permeability ratio was abnormal, despite an unequivocally normal jejunal biopsy (including normal intraepithelial lymphocyte count and disaccharidases). Diagnoses in these patients included idiopathic diarrhoea without malabsorption; severe atopic eczema; folate deficiency (presumed to be nutritional). Many patients with eczema have abnormal immune responses to foods.16 It is likely that local IgE mediated immune reactions to foods are the cause of the permeable intestine, but another explanation is that abnormal permeability to large molecules, sufficient to act as immunogens, is the primary cause of the food allergic state in some patients with atopic eczema.

Clearly, sugar permeability tests have a greater potential in clinical investigation than mere screening tests before jejunal biopsy. We have shown that a cellobiose/mannitol permeability test identifies several groups of patients with subtle nutritional or functional abnormalities. Because permeability tests appear to be abnormal in coeliac disease, Crohn's disease, intestinal infections as well as in food allergic states, investigations of patients with idiopathic diarrhoea or unexplained folate deficiency, seeking evidence of these conditions, may turn out to be fruitful. Finally, it will be important to determine whether increased permeability to large probe molecules is mirrored by increased absorption of food proteins, and whether such phenomena have any pathogenic role in inducing or maintaining harmful immune responses in the gastrointestinal mucosa.

Appendix

**ENZYME ASSAY FOR CELLOBIOSE**

The principle of the method is as follows. One cellobiose molecule reacts with β-glucosidase (Sigma G 8625) to yield two molecules of glucose. D-glucose is then measured using the hexokinase procedure with NADPH generation measured at 340 nM.

**REAGENTS**

β-glucosidase was obtained from Sigma Chemical Company, Dorset, UK. The β-glucosidase reagent contained 35 mg β-glucosidase per ml of acetate buffer (0.1 M pH 5.0). The reagent was prepared freshly before use and was centrifuged at 1600 g for 10 minutes at room temperature. The glucose assay kit was obtained from Sigma Chemical Company, Dorset, UK (Glucose No. 15-UV).
Method

The following were incubated at 37°C with 0.2 ml β-glucosidase reagent: 0.2 ml water (reagent blank, B1), 0.2 ml standard (S), and 0.2 ml filtered urine (U).

The following were incubated at 37°C with 0.2 ml acetate buffer (0.1M, pH 5.0), 0.2 ml filtered urine (urine blank, U0), 0.2 ml standard (standard blank, S0). After two hours, the incubation mixtures were centrifuged for 10 minutes at 1600 g, and 50 µl supernatant was added to 1.2 ml assay reagent; 50 µl water was added to 1.2 ml assay reagent. (Reagent Blank, B2).

After five minutes at room temperature, absorption of the solutions were read at 340 nM on a Pye-Unicam SP 30 UV spectrophotometer with a flow cell attachment. The change in optical density (OD) for a standard containing 1 mg/ml cellobiose is about 0.6 absorbance units.

Calculation:

\[
\% \text{ 5 h cellobiose excretion (5 g dose administered)} = \frac{\Delta \text{OD}(U - U_b) - \Delta \text{OD}(B_1 - B_2)}{\Delta \text{OD}(S - S_b) - \Delta \text{OD}(B_1 - B_2)} \times \frac{5 \text{ h vol (ml)}}{50}
\]

COMMENTS

Experiments in which cellobiose was added to urine and subsequently assayed, showed that the measured cellobiose was 96-108% of the amount added. The reproducibility of the overall technique, for calculation of cellobiose/mannitol ratio was 7.5% within batches, and 10-6% between batches. In areas where there is a high incidence of lactase deficiency, sucrose should be used as sole hyperosmolar agent to avoid abdominal discomfort.

We are grateful to all of those who participated in this study, to the clinical investigation nurses of the Gastro-Intestinal Unit, and to the consultants in the Gastro-Intestinal Unit who have allowed us to study patients in their care. We thank Mrs Doreen Orr for preparation of the manuscript. This work is supported by grants from the Lothian Health Board, the Coeliac Trust and the Scottish Home and Health Department. Dr Stephan Strobel is in receipt of a grant from the Deutsche Forschungsgemeinschaft (DFG Str 210/1).

References